Compliance with oral HRT in postmenopausal women in clinical trials - Meta analysis

Maturitas

Volumn 46, Issue 1, 2003, Pages 33-44

  Shmuely, Yochi ^a   Berlin, Jesse A ^b   Knauss, Jill ^b   Lydick, Eva ^c  

^a PAREXEL INTERNATIONAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Hormone replacement therapy; Meta analysis; Postmenopausal women

Indexed keywords

ESTRADIOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; MENOPAUSAL SYNDROME; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; RANDOMIZATION; STATISTICAL ANALYSIS;

EID: 0041378181     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00155-5     Document Type: Article

References (49)

1. Ellerington M.C., Stevenson J.C. Prevention of osteoporosis: current recommendations. Drugs Aging. 2:1992;508-517.
2. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;605-613.
3. Christiansen C., Christensen M., McNair P., Hagen C., Stocklund K., Transbol I.-B. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur. J. Clin. Invest. 10:1980;273-279.
4. Henderson B.E., Ross R.K., Paganini-Hill A., Mack T.M. Estrogen use and cardiovascular disease. Am. J. Obstet. Gynecol. 154:1986;1181-1186.
5. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
6. Hammond C.B., Nachtigall L.E. Is estrogen replacement therapy necessary. J. Reprod. Med. 30:1985;797-801.
7. Bush T.L., Cowan L.D., Barret-Connor E., et al. Estrogen use and all-cause mortality. Preliminary results from the lipid research clinics program follow-up study. J. Am. Med. Assoc. 249:1983;903-906.
8. Byrd B.F., Burch J.C., Vaughn W.K. The impact of long-term estrogen support after hysterectomy. A report of 1016 cases. Ann. Surg. 185:1977;574-580.
9. Dennerestein L. Depression in menopause. Obstet. Gynecol. Clin. North Am. 14:1987;33-48.
10. Sherwin B.B. Estrogenic effects on memory in women. Ann. New York Acad. Sci. 743:1994;213-230.
11. IMS A.G. IMS dataview data 1994-1998.
12. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288:2002;321-333.
13. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center. Maturitas. 20:1995;91-99.
14. Stumpf P.G., Trocile M.P. Compliance problems with hormone replacement therapy. Obstet. Gynecol. Clin. North Am. 21:1994;219-229.
15. Salamone L.M., Pressman A.R., Seeley D.G., Cauley J.A. Estrogen replacement therapy: a survey of older women's attitudes. Arch. Intern. Med. 156:1996;1293-1297.
16. Nachtigall L. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet. Gynecol. 75:1990;77S.
17. Ravnikar V. Compliance with hormone therapy. Am. J. Obstet. Gynecol. 156:1987;1332.
18. Berman R.S., Epstein R.S., Lydick E.G. Compliance of women in taking estrogen replacement therapy. J. Womens Health. 5:1996;213-220.
19. Berlin J.A., Longnecker P.M., Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 4:1993;218-228.
20. Thacker S.B. Meta-analysis. A quantitative approach to research integration. J. Am. Med. Assoc. 259:1988;1685-1689.
21. AinMelk Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil. Steril. 66:1996;962-968.
22. Barrett-Connor E., Slone S., Greendale G., et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas. 27:1997;261-274.
23. Bolaji I.I., Mortimer G., Grimes H., Tallon D.F., O'Dwyer E., Fottrell P.F. Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women. Gynecol. Endocrinol. 10:1996;41-47.
24. Cosman F., Nieves J., Walliser J., Lindsay R. Postmenopausal osteoporosis: patient choices and outcomesatient choices and outcomes. Maturitas. 22:1995;137-143.
25. Doren M., Reuther G., Minne H., Schneider P.G. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am. J. Obstet. Gynecol. 173:1995;1446-1451.
26. Eiken P., Kolthoff N. Compliance with long-term oral hormonal replacement therapy. Maturitas. 22:1995;97-103.
27. Ferenczy A., Gelfand M. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas. 26:1997;219-226.
28. Giraud G.D., Morton M.J., Wilson R.A., Burry K.A., Speroff L. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Am. J. Obstet. Gynecol. 174:1996;1708-1717.
29. Gordon S.F., Thompson K.A., Ruoff G.E., Imig J.R., Lane P.J., Schwenker C.E. Efficacy and safety of a 7 day, transdermal estradiol drug delivery system: comparison with a conjugated estrogens and placebo. The transdermal estradiol patch study group. Int. J. Fertil. Menopausal Stud. 40:1995;126-134.
30. Haenggi W., Birkhauser M.H. A new peroral estrogen/progestin combination for postmenopausal hormonal substitution: an open multicentric field study. Maturitas. 16:1993;111-122.
31. Hahn R.G., Nachitgall R.D., Davies T.C. Compliance difficulties with progestin supplemented replacement therapy. J. Fam. Pract. 18:1984;411-414.
32. Heikkinen A., Tuppurainen M.T., Niskanen L., Komulainen M., Penttila L., Saarikoski S. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur. J. Endocrinol. 137:1998;495-502.
33. Hilditch J.R., Lewis J., Ross A.H., et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 24:1996;177-184.
34. Hillard T.C., Whitcroft S.J., Marsh M.S., et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int. 4:1994;341-348.
35. Hirvonen E., Lamberg-Allardt C., Lankinen K.C., Geurts P., Wilen-Rosenqvist G. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br. J. Obstet. Gynecol. 104:1994;19-25.
36. Hokkanen T., Hemminki E., Aalton P., et al. Patient managed clinical trial. Control Clin. Trials. 18:1997;140-150.
37. Kemp J.F., Fryer J., Baber R. An alternative regimen of hormone replacement therapy to improve patient compliance. Aust. New Zealand J. Obstet. Gynaecol. 29:1989;66-69.
38. Luciano A.A., DeSouza M.J., Roy M.P., Schoenfeld M.J., Nulsen J.C., Halverson C.V. Evaluation of lower dose estrogen and progestin therapy in postmenopausal women. J. Reprod. Med. 38:1993;207-214.
39. Magos A.L., Brincat M., Studd J.W.W., Wardel P., Schlesinger P., O'Dowd. Amenorrhea and endometrial atrophy with continuous oral estrogen and progesterone therapy in postmenopausal women. Obstet. Gynecol. 65:1985;496-499.
40. Marslewm U., Riis B., Christiansen C. Progestogens: therapeutic and adverse effects in early postmenopausal women. Maturitas. 13:1991;7-16.
41. Meuwissen J.H.J.M., Oddens B.J., Klinkhamer P.J.J.M. Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed estrogen use. Maturitas. 24:1996;21-30.
42. Place V., Powers M., Paul B.S., Darley E., Schenkel L., Good W. A double-blind comparative study of estraderm and premarin in the amelioration of postmenopausal symptoms. Am. J. Obstet. Gynecol. 152:1985;1092-1099.
43. Staland B. Continuous treatment with natural oestrogens and progestogens: a method to avoid endometrial stimulation. Maturitas. 3:1981;145-146.
44. Speroff L., Rowan J., Symons J., Genant H., Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (chart study). J. Am. Med. Assoc. 17:1996;1397-1403.
45. Wallace W.A., Price V.H., Elliot C.A., MacPherson Scott B.W. Hormone replacement therapy acceptability to Nottingham postmenopausal women with a risk factor for osteoporosis. J. R. Soc. Med. 83:1990;699-701.
46. Weinstein L., Bewtra C., Gallagher J.C. Evaluation of continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am. J. Obstet. Gynecol. 162:1990;133-142.
47. Wren B.G., Brown L. Compliance with hormonal replacement therapy. Maturitas. 13:1991;17-21.
48. Rozenberg S., Vandromme J., Kroll M., Pastijn A., Liebens F. Compliance to hormone replacement therapy. Int. J. Fertil. 40:(Suppl. 1):1995;23-32.
49. Hankins C., Lapoint N., Walmsley S. Participation in clinical trials among women living with HIV in Canada. Can. Med. Assoc. J. 159:1998;1359-1365.